

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8312609

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CURIA GLOBAL, INC. (F/K/A ALBANY MOLECULAR RESEARCH, INC.)	10/17/2023
RECEIVING PARTY DATA	
Name:	CONSYNANCE THERAPEUTICS, INC.
Street Address:	11 UNIVERSITY PLACE
City:	RENSSELAER
State/Country:	NEW YORK
Postal Code:	12144
PROPERTY NUMBERS Total: 4	
Property Type	Number
Patent Number:	8802696
Patent Number:	9034899
Patent Number:	9604960
Patent Number:	8815894
CORRESPONDENCE DATA	
Fax Number:	(312)360-9315
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	13123600080
Email:	geinhorn@gbc.law
Correspondent Name:	GREGORY P. EINHORN
Address Line 1:	300 SOUTH WACKER DRIVE
Address Line 2:	SUITE 2500
Address Line 4:	CHICAGO, ILLINOIS 60606
ATTORNEY DOCKET NUMBER:	6739.139059
NAME OF SUBMITTER:	GREGORY P. EINHORN
SIGNATURE:	/Gregory P. Einhorn/
DATE SIGNED:	12/05/2023
Total Attachments: 11	
source=1E02689#page1.tif	
source=1E02689#page2.tif	

source=1E02689#page3.tif
source=1E02689#page4.tif
source=1E02689#page5.tif
source=1E02689#page6.tif
source=1E02689#page7.tif
source=1E02689#page8.tif
source=1E02689#page9.tif
source=1E02689#page10.tif
source=1E02689#page11.tif

ASSIGNMENT

WHEREAS, CURIA GLOBAL, INC. (F/K/A ALBANY MOLECULAR RESEARCH, INC.) a Delaware corporation, (hereinafter "ASSIGNOR"), owns certain inventions and improvements related to 7-([1,2,4]TRIAZOLO[1,5-a]PYRIDINYL-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF, ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF, and CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-1]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF disclosed in United States provisional patent applications identified in Annex A (collectively, the "Priority Documents") and in international and United States patents claiming priority to the Priority Documents including those listed in Annex B (collectively, the "Patents/Applications").

WHEREAS, CONSYNANCE THERAPEUTICS INC. ("ASSIGNEE"), a business entity organized and existing under the laws of the state of Delaware, desires to acquire the ownership of, the entire right, title, and interest in and to said inventions, improvements, know-how, Patents/Applications, and Priority Documents, and in and to any additional Letters Patents which may have or may be granted therefrom.

NOW, THEREFORE, ASSIGNOR assigns the inventions disclosed in the Patents/Applications and Priority Documents to ASSIGNEE, for good and valuable consideration as detailed in the Settlement Agreement and Mutual Release dated October 6, 2023, the receipt and sufficiency of which is hereby acknowledged, and ASSIGNOR by these presents hereby does sell, assign, and transfer, to ASSIGNEE the full, exclusive, and entire right, title, and interest in and to said Patents/Applications, Priority Documents, and in and to all inventions and improvements disclosed and described in said Patents/Applications and Priority Documents, as well as all know-how derived during the development of, and directed to, the inventions and improvements disclosed and described in said Patents/Applications and Priority Documents, and any additional Letters Patents that may have or will grant therefrom.

For the same consideration, ASSIGNOR, by these presents, does sell, assign, and transfer, to ASSIGNEE the full, exclusive, and entire right to claim priority to said Patents/Applications and/or Priority Documents, in whole or in part, arising from or required under the terms of any applicable conventions, treaties, statutes, or regulations.

For the same consideration, ASSIGNOR, by these presents, does sell, assign, and transfer, to ASSIGNEE the full, exclusive, and entire right, title, and interest in and to any other applications that correspond to or claim priority to said Patents/Applications and/or Priority Documents, in whole or in part, and to any Letters Patents and similar protective rights granted on said other applications, and in and to the right to claim any applicable priority rights arising from or required for said other applications under the terms of any applicable conventions, treaties, statutes, or regulations, including to all divisions, continuations, continuations-in-part, or renewals thereof, all Letters Patents which may be granted therefrom, all reexaminations, and all reissues or extensions of such patents; said other applications to be filed and issued in the name of ASSIGNEE or its designee insofar as permitted by applicable law;

AND, for the consideration aforesaid, ASSIGNOR agrees that it will make, execute, and deliver any and all other instruments in writing including any and all further application papers, affidavits, assignments and other documents, and will communicate to said ASSIGNEE, its successors and representatives all facts known to ASSIGNOR relating to said improvements and the history thereof and will testify in all legal proceedings and generally do all things which may be necessary or to secure to and vest in said ASSIGNEE, its successors or assigns the entire right, title, and interest in and to the said improvements, inventions, applications, Letters Patents, rights, titles, benefits, privileges and advantages assigned and conveyed, or intended so to be.

Warranties and Representations

Ownership and Right to Assign. ASSIGNOR represents and warrants that it is the sole and exclusive owner of all rights, title, and interest in and to the Patents/Applications, Priority Documents, and that ASSIGNOR has the full right, power, and authority to assign the same to ASSIGNEE without the need for consent from any third party and without violating the rights of any third party.

No Encumbrances. ASSIGNOR represents and warrants that the Patents/Applications, Priority Documents, are free and clear of any liens, encumbrances, security interests, or other claims.

No Infringement. ASSIGNOR represents and warrants that, to the best of its knowledge, the use or exploitation of the Patents/Applications, Priority Documents, does not infringe upon the rights of any third party.

No Prior Assignments. ASSIGNOR represents and warrants that it has not previously assigned, transferred, licensed, or otherwise encumbered the Patents/Applications, Priority Documents, in any way that would conflict with the rights granted to ASSIGNEE under this Assignment.

Further Assurances. ASSIGNOR agrees to execute any additional documents or take any further actions as may be reasonably necessary to effectuate the intent of this Assignment and to perfect ASSIGNEE's rights hereunder.

AND, furthermore, ASSIGNOR and ASSIGNEE do hereby further acknowledge the assignment of the rights, title, and interests described in this Assignment by affixing their signature below.

Date: 17 OCT 2023

CURIA GLOBAL, INC. (F/K/A ALBANY MOLECULAR RESEARCH, INC.)

BENJAMIN SEIDLER

Title: VP, DEPUTY GENERAL COUNSEL

STATE OF New York County of Albany

Before me, a Notary Public in and for the State of New York, on this 17 day of October, 2023, personally appeared Benjamin Seidler, who, being duly sworn, signed and acknowledged the foregoing Assignment as his/her free act and deed.

LEAH RUTH THREATTE
NOTARY PUBLIC, STATE OF NEW YORK
Registration No. 02TH6415175
(SEAL) Qualified in Alba County
My Commission Expires 02/08/2025

NOTARY PUBLIC

My Commission Expires: 02/08/2025

Date: 18 Oct 2023 Shuang Liu

CONSYNANCE THERAPEUTICS INC.

Title: Shuang Liu
CEO

STATE OF NEW YORK

Before me, a Notary Public in and for the State of NEW YORK, on this
18th day of October, 2023, personally appeared Shuang Liu
_____, who, being duly sworn, signed and acknowledged the foregoing Assignment as his/her free act
and deed.

NOTARY PUBLIC Sarah

(SEAL)

SARAH SILPA TRUMAN
Notary Public, State of New York
Qualified in Albany County
Registration No. 01TR6428832
Commission Expires Jan. 31, 2026

My Commission Expires: 31st January 2026

ANNEX A

Title	Country	Status	Provisional Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Issue Date
7-(1,2,4)TRIAZOLO(1,5- a)PYRIDINYL-6-YL)-4-(3,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	US	Expired	61/177,474	5/12/2009	N/A	N/A	N/A	N/A
ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF	US	Expired	61/177,464	5/12/2009	N/A	N/A	N/A	N/A
CRYSTALLINE FORMS OF (S)- 7-(1,2,4)TRIAZOLO(1,5- 1)PYRIDIN-6-YL)-4-(3,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	US	Expired	61/177,486	5/12/2009	N/A	N/A	N/A	N/A

ANNEX B

TITLE	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Issue Date
7-((1,2,4)TRIAZOLO[1,5- a]PYRIDINYL-6-YL)-4-(3,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	AU	In Force	2010247763	5/11/2010	2010247763		2010247763	4/7/2016
7-((1,2,4)TRIAZOLO[1,5- a]PYRIDINYL-6-YL)-4-(3,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	BE	In Force	10775398.0	5/11/2010	2429296	3/21/2012	2429296	12/27/2017
7-((1,2,4)TRIAZOLO[1,5- a]PYRIDINYL-6-YL)-4-(3,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	CA	In Force	2,760,837	5/11/2010	2760837	11/18/2010	2760837	4/3/2018
7-((1,2,4)TRIAZOLO[1,5- a]PYRIDINYL-6-YL)-4-(3,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	CH	In Force	10775398.0	5/11/2010	2429296	9/21/2012	2429296	12/27/2017
7-((1,2,4)TRIAZOLO[1,5- a]PYRIDINYL-6-YL)-4-(3,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	CN	In Force	201080031617.X	5/11/2010	102593902	7/18/2012	ZL201080031617.X	4/29/2015
7-((1,2,4)TRIAZOLO[1,5- a]PYRIDINYL-6-YL)-4-(3,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	DE	In Force	10775398.0	5/11/2010	2429296	3/21/2012	2429296	12/27/2017
7-((1,2,4)TRIAZOLO[1,5- a]PYRIDINYL-6-YL)-4-(3,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	DK	In Force	10775398.0	5/11/2010	2429296	3/21/2012	2429296	12/27/2017

TITLE	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Issue Date
7-((1,2,4)TRIAZOLO[1,5- ajPYRIDINYL-6-YL)-4-(3,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	EP	Lapsed	10775398.0	5/11/2010	2429296	3/21/2012	2429296	12/27/2017
7-((1,2,4)TRIAZOLO[1,5- ajPYRIDINYL-6-YL)-4-(3,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	ES	In Force	10775398.0	5/11/2010	2429296	3/21/2012	2429296	12/27/2017
7-((1,2,4)TRIAZOLO[1,5- ajPYRIDINYL-6-YL)-4-(3,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	FR	In Force	10775398.0	5/11/2010	2429296	3/21/2012	2429296	12/27/2017
7-((1,2,4)TRIAZOLO[1,5- ajPYRIDINYL-6-YL)-4-(3,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	GB	In Force	10775398.0	5/11/2010	2429296	3/21/2012	2429296	12/27/2017
7-((1,2,4)TRIAZOLO[1,5- ajPYRIDINYL-6-YL)-4-(3,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	HK	In Force	12102904.7	5/11/2010	1162249A	8/31/2012	1162249	1/4/2019
7-((1,2,4)TRIAZOLO[1,5- ajPYRIDINYL-6-YL)-4-(3,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	IE	In Force	10775398.0	5/11/2010	2429296	3/21/2012	2429296	12/27/2017
7-((1,2,4)TRIAZOLO[1,5- ajPYRIDINYL-6-YL)-4-(3,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	IL	In Force	216049	5/11/2010	216049	9/30/2014	216049	12/31/2014
7-((1,2,4)TRIAZOLO[1,5- ajPYRIDINYL-6-YL)-4-(3,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	IS	In Force	10775398.0	5/11/2010	2429296	3/21/2012	2429296	12/27/2017

PATENT

REEL: 065771 FRAME: 0528

TITLE	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Issue Date
7-(1,2,4)TRIAZOLO[1,5- ajPYRIDINYL-6-YL]-4-G,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	IT	In Force	10775398.0	5/11/2010	2429296	3/21/2012	2429296	12/27/2017
7-(1,2,4)TRIAZOLO[1,5- ajPYRIDINYL-6-YL]-4-G,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	JP	In Force	2012-510933	5/11/2010	2012-526825	11/1/2012	5764553	6/19/2015
7-(1,2,4)TRIAZOLO[1,5- ajPYRIDINYL-6-YL]-4-G,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	KR	In Force	10-2011-7029368	5/11/2010	10-1830447		10-1830447	2/12/2018
7-(1,2,4)TRIAZOLO[1,5- ajPYRIDINYL-6-YL]-4-G,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	LI	In Force	10775398.0	5/11/2010	2429296	3/21/2012	2429296	12/27/2017
7-(1,2,4)TRIAZOLO[1,5- ajPYRIDINYL-6-YL]-4-G,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	NZ	In Force	596104	5/11/2010	596104		596104	5/1/2014
7-(1,2,4)TRIAZOLO[1,5- ajPYRIDINYL-6-YL]-4-G,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	US	In Force	12777.776	5/11/2010	US20100292243	11/18/2010	8,802,696	8/12/2014
7-(1,2,4)TRIAZOLO[1,5- ajPYRIDINYL-6-YL]-4-G,4- DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF	ZA	In Force	2011/07909	5/11/2010	2011/07909		2011/07909	1/30/2013
ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF	US	In Force	12777.778	5/11/2010	US20100292242	11/18/2010	9,034,899	5/19/2015

TITLE	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Issue Date
ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF	US	In Force	14/593,750	1/9/2015	US20150126517	5/7/2015	9,604,960	3/28/2017
ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF	VE	Pending	756/2010	5/11/2010				
CRYSTALLINE FORMS OF (S)-7-((1,2,4)TRIAZOLO(1,5- η 1)PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF	DE	In Force	10775425.1	5/11/2010	2429293	3/21/2012	2429293	10/29/2014
CRYSTALLINE FORMS OF (S)-7-((1,2,4)TRIAZOLO(1,5- η 1)PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF	ES	In Force	10775425.1	5/11/2010	ES252840473	2/10/2015	2429293	10/29/2014
CRYSTALLINE FORMS OF (S)-7-((1,2,4)TRIAZOLO(1,5- η 1)PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF	FR	In Force	10775425.1	5/11/2010	2429293	3/21/2012	2429293	10/29/2014
CRYSTALLINE FORMS OF (S)-7-((1,2,4)TRIAZOLO(1,5- η 1)PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF	GB	In Force	10775425.1	5/11/2010	2429293	3/21/2012	2429293	10/29/2014
CRYSTALLINE FORMS OF (S)-7-((1,2,4)TRIAZOLO(1,5- η 1)PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF	IT	In Force	10775425.1	5/11/2010	2429293	3/21/2012	2429293	10/29/2014

TITLE	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Issue Date
CRYSTALLINE FORMS OF (S)-7-(1,2,4)TRIAZOLO(1,5-f)PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF	JP	In Force	2012-510952	5/11/2010	2012-526827	11/1/2012	5739415	5/1/2015
CRYSTALLINE FORMS OF (S)-7-(1,2,4)TRIAZOLO(1,5-f)PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF	US	In Force	12/777,840	5/11/2010	US20100292250	11/18/2010	8,815,894	8/26/2014